Pulmatrix, Inc. (PULM) - Form 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Pulmatrix, Inc. is a biopharmaceutical company developing inhaled therapeutic products using its proprietary iSPERSE™ technology. The company's operations are currently in a strategic transition phase, with all clinical development paused while it pursues a merger with Eos SENOLYTIX, Inc. (the "Merger").
On March 26, 2026, Pulmatrix entered into a Merger Agreement with Eos. Upon closing, Eos stockholders are expected to own approximately 94% of the combined company, while existing Pulmatrix stockholders will own approximately 6%. The company has stated that if the Merger is not consummated, the board may pursue dissolution and liquidation.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | As of June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1.036) million | $(2.208) million | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.29) | $(0.61) | N/A |
| Operating Expenses | $(1.046) million | $(2.338) million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2.168 million |
| Restricted Cash | N/A | N/A | $0.700 million |
| Total Assets | N/A | N/A | $3.246 million |
| Total Liabilities | N/A | N/A | $0.689 million |
| Stockholders' Equity | N/A | N/A | $2.557 million |
Note: Financial figures are in thousands unless otherwise noted. The company reported no revenue for the periods presented.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $0.5 million for the three months ended June 30, 2026, compared to the same period in 2025. This reduction was driven by lower costs related to software subscriptions, legal/patent fees, and business development activities.
- Net Loss: The net loss for the six months ended June 30, 2026, was $2.208 million, a decrease of $1.149 million compared to the $3.357 million loss in the prior year period.
- Financing Activity: In the first quarter of 2026, the company raised $1.0 million in gross proceeds through the sale of Series B Convertible Preferred Stock to an affiliate of Eos. This contrasts with no financing proceeds in the prior year period.
- Balance Sheet: Cash and cash equivalents decreased from $4.088 million at December 31, 2025, to $2.168 million at June 30, 2026. However, $0.7 million of the proceeds from the preferred stock issuance is currently classified as restricted cash.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the issuance of these financial statements, absent the closing of the Merger. The company anticipates its current cash position is sufficient only through the anticipated closing of the Merger.
- Merger Dependency: Future operations are highly dependent on the success of the Merger with Eos. If the Merger fails, the company may seek other strategic alternatives or pursue dissolution and liquidation.
- Product Development: All clinical development for product candidates (PUR3100, PUR1800, PUR1900) is currently on hold. The company is exploring opportunities to monetize or license these assets.
- Series B Preferred Stock: The company issued 1,000 shares of Series B Convertible Preferred Stock. These shares accrue cumulative dividends at 8.0% per annum, payable in common stock upon conversion. As of June 30, 2026, $16,000 in dividends had accrued.
- Risks: Key risks include the failure to obtain stockholder approval for the Merger, inability to secure additional funding if the Merger fails, and the general uncertainties associated with biopharmaceutical development.
Investor Verification Checklist
- Merger Status: Verify the current status of the Merger Agreement with Eos SENOLYTIX, Inc., including any updates on shareholder approval or regulatory filings (Form S-4).
- Liquidity Runway: Confirm the company's cash burn rate and whether the $2.2 million in unrestricted cash is sufficient to cover merger-related costs and operations until closing.
- Restricted Cash Terms: Review the specific conditions under which the $0.7 million in restricted cash will be released (e.g., consummation of Merger or termination of the agreement).
- Preferred Stock Dilution: Assess the potential dilution impact of the Series B Convertible Preferred Stock and its accrued dividends upon conversion to common stock.
- Asset Monetization: Monitor any announcements regarding the licensing or sale of the paused clinical assets (PUR3100, PUR1800, PUR1900) if the Merger does not proceed.